<DOC>
	<DOC>NCT02318719</DOC>
	<brief_summary>Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo</brief_summary>
	<brief_title>DS-5565 Phase III Study for Post-herpetic Neuralgia</brief_title>
	<detailed_description>[Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian subjects with PHN receiving DS-5565 versus placebo. [Open Extension Phase] The objective is to assess the long-term safety and efficacy of DS-5565 in subjects with PHN.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<criteria>PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening At screening, a pain scale of â‰¥ 40 mm Previous use of neurolytic block</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Post-Herpetic Neuralgia</keyword>
</DOC>